Palvella Therapeutics (PVLA) Stock Forecast & Price Target

Compare

681 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PVLA Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Palvella

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$132.55

▲(32.56% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $132.55 with a high forecast of $200.00 and a low forecast of $70.00. The average price target represents a 32.56% change from the last price of $99.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","106":"$106","201":"$201","58.5":"$58.5","153.5":"$153.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":132.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$132.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,58.5,106,153.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.84,89.08307692307693,98.32615384615386,107.56923076923077,116.8123076923077,126.05538461538463,135.29846153846154,144.54153846153847,153.7846153846154,163.02769230769232,172.27076923076925,181.51384615384615,190.7569230769231,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.84,83.89461538461539,87.94923076923078,92.00384615384615,96.05846153846154,100.11307692307693,104.1676923076923,108.2223076923077,112.27692307692308,116.33153846153847,120.38615384615386,124.44076923076923,128.49538461538464,{"y":132.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,79.84,79.08307692307693,78.32615384615384,77.56923076923077,76.8123076923077,76.05538461538461,75.29846153846154,74.54153846153847,73.78461538461539,73.0276923076923,72.27076923076923,71.51384615384616,70.75692307692307,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$132.55

Lowest Price Target$70.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Annabel Samimy

Stifel Nicolaus

$87→$145

Buy

45.01%

Upside

Reiterated

11/24/25

Stifel Nicolaus Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Whitney Ijem

Canaccord Genuity

$148

Buy

48.01%

Upside

Reiterated

11/24/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (NASDAQ: SGMT), Bristol-Myers Squibb (NYSE: BMY) and Palvella Therapeutics (NASDAQ: PVLA)Contact your Institutional Salesperson to register for our KOL call TOMORROW at 3:00pm ET.

Ryan Deschner

Raymond James

$92→$143

Buy

43.01%

Upside

Upgraded

11/19/25

Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesPalvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Sam Slutsky

LifeSci Capital

$130

Buy

30.01%

Upside

Reiterated

11/15/25

Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital

Andrew Fein

H.C. Wainwright

$190

Buy

90.02%

Upside

Reiterated

11/12/25

Buy Rating Affirmed for Palvella Therapeutics: QTORIN Platform Expansion and Potential FDA Approval Drive OptimismValuation and Risks. Our price target of $190 is based on an equally weighted composite of: (a) $197.5/share, as a 15x multiple of taxed and diluted $42.83 discounted back to and (b) an NPV of $181.6/share (discounted cash flow analysis using a 14% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Palvella completed a reverse merger with December 2024.

Geulah Livshits

Chardan Capital

$110

Buy

10.01%

Upside

Reiterated

11/12/25

Chardan Capital Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Ritu Baral

TD Cowen

$97

Buy

-2.99%

Downside

Reiterated

11/11/25

Palvella Therapeutics: Strong Financial Position and Promising Clinical Trials Drive Buy Rating

Trevor Allred

Oppenheimer

$100→$120

Buy

20.01%

Upside

Reiterated

11/11/25

Palvella Therapeutics price target raised to $120 from $100 at OppenheimerPalvella Therapeutics price target raised to $120 from $100 at Oppenheimer

Danielle Brill

Truist Financial

$80→$105

Buy

5.01%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Tandem Diabetes Care (NASDAQ: TNDM) and Palvella Therapeutics (NASDAQ: PVLA)

Joshua Schimmer

Cantor Fitzgerald

$120→$200

Buy

100.02%

Upside

Reiterated

11/06/25

Palvella price target raised to $200 from $120 at Cantor FitzgeraldPalvella price target raised to $200 from $120 at Cantor Fitzgerald

Catherine Novack

JonesTrading

$56→$70

Buy

-29.99%

Downside

Reiterated

09/25/25

JonesTrading Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Louise Chen

Scotiabank

$50

Buy

-49.99%

Downside

Reiterated

07/22/25

Scotiabank Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Dev Prasad

Lucid Capital

$49

Buy

-51.00%

Downside

Initiated

03/18/25

Lucid Capital Markets starts Palvella Therapeutics (PVLA) at Buy, PT $49Lucid Capital Markets analyst Dev Prasad initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Buy rating and a price target of $49.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Annabel Samimy

Stifel Nicolaus

$87→$145

Buy

45.01%

Upside

Reiterated

11/24/25

Stifel Nicolaus Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Whitney Ijem

Canaccord Genuity

$148

Buy

48.01%

Upside

Reiterated

11/24/25

Ryan Deschner

Raymond James

$92→$143

Buy

43.01%

Upside

Upgraded

11/19/25

Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesPalvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Sam Slutsky

LifeSci Capital

$130

Buy

30.01%

Upside

Reiterated

11/15/25

Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital

Andrew Fein

H.C. Wainwright

$190

Buy

90.02%

Upside

Reiterated

11/12/25

Geulah Livshits

Chardan Capital

$110

Buy

10.01%

Upside

Reiterated

11/12/25

Chardan Capital Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

Ritu Baral

TD Cowen

$97

Buy

-2.99%

Downside

Reiterated

11/11/25

Palvella Therapeutics: Strong Financial Position and Promising Clinical Trials Drive Buy Rating

Trevor Allred

Oppenheimer

$100→$120

Buy

20.01%

Upside

Reiterated

11/11/25

Palvella Therapeutics price target raised to $120 from $100 at OppenheimerPalvella Therapeutics price target raised to $120 from $100 at Oppenheimer

Danielle Brill

Truist Financial

$80→$105

Buy

5.01%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Tandem Diabetes Care (NASDAQ: TNDM) and Palvella Therapeutics (NASDAQ: PVLA)

Joshua Schimmer

Cantor Fitzgerald

$120→$200

Buy

100.02%

Upside

Reiterated

11/06/25

Palvella price target raised to $200 from $120 at Cantor FitzgeraldPalvella price target raised to $200 from $120 at Cantor Fitzgerald

Catherine Novack

JonesTrading

$56→$70

Buy

-29.99%

Downside

Reiterated

09/25/25

JonesTrading Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Louise Chen

Scotiabank

$50

Buy

-49.99%

Downside

Reiterated

07/22/25

Scotiabank Keeps Their Buy Rating on Palvella Therapeutics (PVLA)

Dev Prasad

Lucid Capital

$49

Buy

-51.00%

Downside

Initiated

03/18/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

1 Month

xxx

Success Rate

5/5 ratings generated profit

Average Return

+30.24%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +30.24% per trade.

3 Months

xxx

Success Rate

5/5 ratings generated profit

Average Return

+68.40%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +68.40% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

9/9 ratings generated profit

Average Return

+313.62%

reiterated a buy rating 18 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +313.62% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+313.62%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +313.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PVLA has received 34 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 132.55.

Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

Next quarter’s earnings estimate for PVLA is -$0.90 with a range of -$1.06 to -$0.30. The previous quarter’s EPS was -$1.03. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Sales Forecast

Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 132.55.

What is PVLA’s upside potential, based on the analysts’ average price target?

Palvella Therapeutics has 32.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PVLA a Buy, Sell or Hold?

Palvella Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Palvella Therapeutics’s price target?

The average price target for Palvella Therapeutics is 132.55. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $70.00. The average price target represents 32.56% Increase from the current price of $99.99.

What do analysts say about Palvella Therapeutics?

Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of PVLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

PVLA Analyst Ratings

PVLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Palvella Therapeutics

PVLA Analyst Recommendation Trends

PVLA Financial Forecast

PVLA Earnings Forecast

PVLA Sales Forecast

PVLA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts